Novavax Inc (NVAX): Net Income
$440.30M
Year ended 2025-12-31
-$247.73M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $440.30M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$187.50M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$545.06M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$657.94M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$1.74B | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$418.26M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$132.69M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$184.75M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$183.77M | n/m | 2020-03-11, From 2017-01-01 |
| 2016-12-31 | -$279.97M | n/m | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | -$156.94M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | -$82.95M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$51.98M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$28.51M | n/m | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | -$19.36M | n/m | 2014-03-12, From 2011-01-01 |
| 2010-12-31 | -$35.71M | n/m | 2013-03-12, From 2010-01-01 |
| 2009-12-31 | -$40.35M | n/a | 2012-03-14, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Novavax Inc (NVAX) | 2025-12-31 | $440.30M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $181.86M | +147.8% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $316.89M | -28.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $263.86M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $48.89M | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$2.82B | n/m |
| Qiagen N.V. (QGEN) | 2025-12-31 | $424.88M | +408.3% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $782.57M | +50.1% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.93M | -25.7% |
Compare NVAX, TECH, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗